{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12","upperLimit":"68","value":"25"},{"groupId":"OG001","lowerLimit":"12","upperLimit":"28","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Progressive Disease (PD) is defined per International Myeloma Working Group (IMWG) Uniform Response Criteria guidelines is an increase of 25% from the lowest response value in any one or more of the following: Serum M-component and/or Urine M-component and/or in patients without a measurable serum and urine M protein level: the difference between involved and uninvolved FLC levels must be \\>10mg/dL, Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing lesions or plasmacytomas, Development of hypercalcemia attributed solely to the plasma cell proliferative disorder","dispersionType":"Inter-Quartile Range","groups":[{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib: Phase I: Level -1 = 20 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"OG000","title":"Level -1 = 20 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib: Phase I: Level 0 = 40 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"OG001","title":"Level 0 = 40 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib: Phase I: Level +1 = 60 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"OG002","title":"Level +1 = 60 mg"}],"paramType":"MEDIAN","populationDescription":"No subjects were dosed at 60 mg dose level.","reportingStatus":"POSTED","timeFrame":"variable, defined by individual response durability in individual patients who would stay on therapy until disease progression","title":"Response Durability Assessed by Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"weeks"}